Literature DB >> 29926143

Certainties and Uncertainties About Denosumab Discontinuation.

Elena Tsourdi1,2, M Carola Zillikens3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29926143     DOI： 10.1007/s00223-018-0436-y

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  6 in total

1.  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Maria P Yavropoulou; Charikleia Ntenti; Stylianos Mandanas; Polyzois Makras
Journal:  Endocrine       Date:  2021-03-02       Impact factor: 3.633

2.  Temporomandibular Joint Hypofunction Secondary to Unilateral Partial Discectomy Attenuates Degeneration in Murine Mandibular Condylar Cartilage.

Authors:  Mamoru Yotsuya; Jose Iriarte-Diaz; David A Reed
Journal:  Bull Tokyo Dent Coll       Date:  2020-02-27

Review 3.  Stopping Denosumab.

Authors:  Olivier Lamy; Delphine Stoll; Bérengère Aubry-Rozier; Elena Gonzalez Rodriguez
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

Review 4.  Should denosumab treatment for osteoporosis be continued indefinitely?

Authors:  Jane A Noble; Malachi J McKenna; Rachel K Crowley
Journal:  Ther Adv Endocrinol Metab       Date:  2021-04-22       Impact factor: 3.565

5.  Zoledronic Acid Ameliorates the Bone Turnover Activity and Periprosthetic Bone Preservation in Cementless Total Hip Arthroplasty.

Authors:  Allen Herng Shouh Hsu; Chun-Hsien Yen; Feng-Chih Kuo; Cheng-Ta Wu; Tsan-Wen Huang; Juei-Tang Cheng; Mel S Lee
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-30

Review 6.  Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.

Authors:  Kent Søe
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.